Earnings Releases·Nov 2, 2026, 4:07 PM ET

Cerus Corporation — Third Quarter 2026 Earnings Summary

Total revenue increased 11% year-over-year to $64.0 million, driven by a 10% rise in product revenue to $57.7 million, while government contract revenue declined 16% to $6.3 million.
Net loss narrowed significantly to $0.6 million for the quarter and $5.1 million for the first nine months, compared to $13.4 million in the same 2025 period, with non-GAAP adjusted EBITDA improving to $5.7 million for the quarter.
The company reiterated full-year 2026 product revenue guidance of $229 million to $231 million and IFC revenue guidance of $23 million to $25 million, supported by 80% growth in IFC volumes.
The Phase 3 RedeS trial for the INTERCEPT Blood System for red blood cells achieved positive topline results, and the company announced the appointment of Betsy Jensen as chief human resources officer effective December 2026.